Insulin Receptor Substrate 1 (IRS-1)

Introduction

Insulin Receptor Substrate 1 (Irs 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Introduction

Insulin Receptor Substrate 1 (Irs 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Insulin receptor substrate 1 ([IRS-1) is a 131 kDa signaling adaptor protein that serves as the primary intracellular mediator of insulin and insulin-like growth factor 1 (IGF-1) receptor signaling. Encoded by the IRS1 gene on chromosome 2q36.3, [irs-1](/entities/irs-1) acts as a docking platform that is phosphorylated on tyrosine residues by activated insulin/IGF-1 receptors, subsequently recruiting downstream effectors including PI3K/[akt-protein](/proteins/akt-protein) and Ras/MAPK pathways that regulate glucose metabolism, cell survival, synaptic plasticity, and [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) ([White, 2003](https://doi.org/10.1126/science.1092952)).

[irs-1](/entities/irs-1) dysregulation has emerged as a critical molecular link between brain insulin resistance and [alzheimers](/diseases/alzheimers-disease) (AD), earning AD the designation "type 3 diabetes." In AD brain tissue, [irs-1](/entities/irs-1) exhibits pathological serine hyperphosphorylation (which inhibits its function) while tyrosine phosphorylation (which activates signaling) is reduced, resulting in impaired insulin/IGF-1 signaling that promotes tau] hyperphosphorylation, [amyloid-beta](/proteins/amyloid-beta) accumulation, synaptic dysfunction, and neuronal death ([Talbot et al., 2012](https://doi.org/10.1172/JCI59903)).

Structure and Function

Protein Domains

[irs-1](/entities/irs-1) contains several functional domains:

• Pleckstrin Homology (PH) domain: Mediates membrane localization via phosphoinositide binding, bringing [irs-1](/entities/irs-1) into proximity with the insulin receptor
• Phosphotyrosine Binding (PTB) domain: Binds the NPXY motif of the activated insulin receptor
• Multiple tyrosine phosphorylation sites: ~20 tyrosine residues serve as docking sites for SH2 domain-containing proteins when phosphorylated (PI3K regulatory subunits p85α/β, Grb2, SHP2, Nck)
• Multiple serine/threonine phosphorylation sites: >50 serine/threonine residues that, when phosphorylated, generally inhibit [irs-1](/entities/irs-1) function (negative feedback or pathological inhibition)

Signaling Cascades

When insulin or IGF-1 binds its receptor, the receptor autophosphorylates and then tyrosine-phosphorylates [irs1](/entities/irs1), initiating two major pathways:

PI3K/Akt Pathway (Metabolic)

Ras/MAPK Pathway (Mitogenic)

Brain-Specific Functions

In the brain, insulin/IGF-1 signaling via IRS-1 is essential for:

• Synaptic plasticity and memory: Insulin signaling facilitates [long-term-potentiation](/mechanisms/long-term-potentiation) in the [hippocampus](/brain-regions/hippocampus) and promotes AMPA receptor trafficking to synapses
• [tau-protein](/proteins/tau) phosphorylation regulation: Akt-mediated [gsk3-beta](/mechanisms/gsk3-beta) inhibition is the primary mechanism preventing pathological [tau](/proteins/tau) hyperphosphorylation
• Neuronal survival: Anti-apoptotic signaling through Akt/FoxO and Bcl-2 family regulation
• Glucose metabolism: Neuronal glucose uptake and utilization, particularly in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex)
• [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration) regulation: mTORC1-dependent regulation of macroautophagy and [tfeb](/proteins/tfeb) nuclear translocation

IRS-1 in Alzheimer's Disease

Brain Insulin Resistance

Brain insulin resistance in AD is characterized by impaired IRS-1 signaling:

• Serine hyperphosphorylation: In AD brain, IRS-1 is pathologically phosphorylated on inhibitory serine residues (Ser312, Ser616, Ser636/639) by stress kinases including JNK, IKKβ, PKR, and [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration). This serine phosphorylation blocks tyrosine phosphorylation and promotes IRS-1 degradation ([Bomfim et al., 2012](https://doi.org/10.1172/JCI57256))
• Reduced tyrosine phosphorylation: Activating tyrosine phosphorylation of IRS-1 is decreased by ~50% in AD [hippocampus](/brain-regions/hippocampus) compared to controls
• Reduced insulin receptor expression: Insulin receptor density and insulin receptor tyrosine kinase activity are decreased in AD brain
• Elevated IRS-1 pSer in CSF/plasma: Phospho-Ser312 and phospho-Ser616 IRS-1 are elevated in AD patient [exosomes](/entities/exosomes) and CSF, serving as potential [biomarkers](/biomarkers)

Downstream Consequences

IRS-1 dysfunction in AD produces multiple pathological effects:

• [Tau](/proteins/tau) hyperphosphorylation at multiple epitopes (Thr181, Ser202/Thr205, Thr231)
• Glycogen metabolism disruption
• Increased [amyloid-beta](/proteins/amyloid-beta) production via [app](/genes/app) processing modulation

• Impaired [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration), reducing clearance of [amyloid-beta](/proteins/amyloid-beta) and tau aggregates
• Translational dysregulation
• [tfeb](/proteins/tfeb) nuclear exclusion, impairing lysosomal biogenesis

• AMPA receptor surface expression
• [bdnf](/proteins/bdnf) signaling
• Dendritic spine density
• [long-term-potentiation](/mechanisms/long-term-potentiation) in hippocampal circuits

Aβ-Induced Insulin Resistance

[amyloid-beta](/proteins/amyloid-beta) oligomers directly induce IRS-1 dysfunction through:

• Binding to and removing insulin receptors from the neuronal surface
• Activating TNFα/JNK signaling cascades that serine-phosphorylate IRS-1
• Competing with insulin for receptor binding
• Activating PKR (double-stranded RNA-dependent protein kinase), which phosphorylates eIF2α and IRS-1

Therapeutic Implications

Insulin-Sensitizing Strategies

Targeting brain insulin resistance via IRS-1 pathways is an active area of AD therapeutics:

• Intranasal insulin: Bypasses the [blood-brain-barrier](/entities/blood-brain-barrier); clinical trials show improved cognition and reduced brain hypometabolism in MCI/mild AD. Phase II/III trials have yielded mixed but encouraging results ([Craft et al., 2020](https://doi.org/10.1001/jamaneurol.2019.3544))
• [glp1-receptor-agonists](/therapeutics/glp1-receptor-agonists): Liraglutide, semaglutide, and exenatide enhance [brain insulin signaling](/entities/brain-insulin-signaling) and reduce IRS-1 serine phosphorylation. The ELAD trial of liraglutide in AD showed reduced cerebral glucose decline. Semaglutide is in Phase III AD trials.
• Metformin: AMPK activator that improves insulin sensitivity; epidemiological studies show reduced AD risk in diabetic patients taking metformin
• PPARγ agonists: Rosiglitazone and pioglitazone improve insulin sensitivity; pioglitazone showed promise in AD prevention trials (TOMORROW trial)

Kinase Inhibitors

• JNK inhibitors: Block stress-kinase-mediated IRS-1 serine phosphorylation
• GSK-3 inhibitors: [tideglusib](/therapeutics/tideglusib), lithium, and other [gsk3-beta](/mechanisms/gsk3-beta) inhibitors address downstream consequences of IRS-1 dysfunction
• [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration) modulators: Rapamycin analogs restore [autophagy](/entities/autophagy) in AD models

IRS-1 vs. IRS-2 in Brain

While IRS-1 is the predominant insulin signaling mediator, IRS-2 also plays important brain roles:

| Feature | IRS-1 | IRS-2 |
|---------|-------|-------|
| Primary receptor | Insulin receptor, IGF-1R | Insulin receptor, IGF-1R |
| Brain expression | Widespread, enriched in [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex) | Widespread, enriched in hypothalamus |
| AD involvement | Serine hyperphosphorylation → signaling blockade | Expression reduced in AD |
| Mouse knockout | Insulin resistance, growth retardation | Diabetes, reduced brain size |
| Amyloid effect | IRS-1 dysfunction increases [amyloid-beta](/proteins/amyloid-beta) | IRS-2 deletion reduces [amyloid-beta](/proteins/amyloid-beta) (paradoxically) |

Background

The study of Insulin Receptor Substrate 1 (Irs 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Brain Atlas Resources

• Allen Human Brain Atlas: [Insulin Receptor Substrate 1 expression search](https://human.brain-map.org/microarray/search/show?search_term=Insulin+Receptor+Substrate+1)
• Allen Mouse Brain Atlas: [Insulin Receptor Substrate 1 search](https://mouse.brain-map.org/search/index.html?query=Insulin+Receptor+Substrate+1)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [Insulin Receptor Substrate 1 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Insulin+Receptor+Substrate+1)
• microglia - [Genes Index/genes)
• Mechanisms of Neurodegeneration
• [Proteins Index

External Links

• [NCBI Gene](https://www.ncbi.nlm.nih.gov/gene/)
• [UniProt](https://www.uniprot.org/)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)